ChemoMetec Q1 Revenue Rises 28%, EBITDA Up 46%; Raises Guidance
Q1 2026/27 revenue rose 28% year over year to DKK 160.0 million, while EBITDA increased 46% to DKK 100.3 million. ChemoMetec upgraded full-year revenue guidance to DKK 570–605 million and EBITDA guidance to DKK 335–360 million on November 3, 2026.
Q1 2026/27 revenue rose 28% year over year to DKK 160.0M and EBITDA rose 46% to DKK 100.3M. The company expects full-year revenue of DKK 570—605M and EBITDA of DKK 335—360M; guidance was upgraded on 3 November 2026.Material DetailsContext by AI AnalystThis is an early-quarter update showing acceler…